statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TFF Pharmaceuticals ( NASDAQ:TFFP ) Full Year 2023 Results Key Financial Results Net loss: US$21.2m (loss narrowed by...

TFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectations

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
TFFP stock results show that TFF Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the fourth...

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

TFF Pharmaceuticals reports Q4 EPS ($2.01) vs. ($6.13) last year

FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) ( the Company ), a clinical-stage biopharmaceutical company focused on developing and commercializing...

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP  Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Short Interest Update

Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to...

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Oral Presentation to Present Updated Data from Phase 2 Trial Demonstrating Successful Transition of Patients from Oral Tacrolimus to TFF TACFORT WORTH, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- TFF...

TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (I

FORT WORTH, Texas, March 22, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the Company or TFF Pharmaceuticals ), a clinical-stage biopharmaceutical company focused on...

TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TFF Pharmaceuticals trading resumes

FORT WORTH, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the Company or TFF Pharmaceuticals ), a clinical-stage biopharmaceutical company focused on developing and...

TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.

Volume	7,469.00
52-Wk High	$21.25
52-Wk Low	$2.51

TFFP Tff Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals